Solitary Plasmacytoma and Extramedullary Plasmacytoma

Article written and reviewed by Dr Luca Moretti

Solitary plasmacytoma is a rare monoclonal plasma cell neoplasm characterized by a single tumor mass in bone or an extramedullary site, without the systemic involvement typical of multiple myeloma. Its identification is crucial because it lies on a biologic spectrum ranging from a low-risk localized neoplasm to potential progression to systemic disease, with major implications for prognosis and therapeutic management.

The classification distinguishes:

• Solitary bone plasmacytoma (SBP): a plasma cell tumor confined to a single skeletal site, with no other osteolytic lesions, no clonal bone marrow plasma cells in pure plasmacytoma or a clonal proportion below 10% in plasmacytoma with minimal bone marrow involvement, and no clinical or laboratory evidence of systemic disease, with negative CRAB and SLiM criteria.
• Solitary extramedullary plasmacytoma (EMP): a plasma cell tumor arising in soft tissues outside the skeleton, most often at sites rich in lymphoid tissue such as the upper respiratory tract, but potentially in any organ.

Both forms lack evidence of active multiple myeloma at diagnosis, but they differ in epidemiology, molecular biology, natural history and risk of progression.

Prompt recognition of these entities and distinction from early multiple myeloma are essential for selecting targeted treatment strategies and monitoring the risk of systemic progression.

Etiology, pathogenesis and pathophysiology

Solitary plasmacytoma is a rare plasma cell neoplasm characterized by localized monoclonal proliferation of mature B-cell-derived cells at an osseous site, solitary bone plasmacytoma (SBP), or in soft tissues, extramedullary plasmacytoma (EMP). The etiopathogenetic mechanism leading to formation of a single tumor mass without other bone marrow sites or a diffuse myelomatous component remains partly unclear and is one of the major current challenges in hematologic oncology research.

Etiologically, no direct causal factors have been clearly identified. However, clonal evolution of abnormal plasma cells appears to require a specific tissue microenvironment favoring localized growth. Unlike multiple myeloma, no infectious agents, toxic exposures or germline genetic abnormalities have been established as definite causes of plasmacytoma. No specific validated predisposing factors have been defined. Nonconclusive associations have been reported with:

• No specific causal environmental factors have been defined; age, site, lesion size, persistence of the monoclonal component and minimal bone marrow involvement have mainly prognostic value.

The absence of a direct causal relationship between these factors and plasmacytoma currently makes effective primary prevention strategies impossible.

Pathogenetically, solitary plasmacytoma arises from the neoplastic transformation of a post-germinal-center B cell that has acquired the ability to terminally differentiate into a monoclonal immunoglobulin-secreting plasma cell. Solitary plasmacytoma shares clonal abnormalities with myeloma; the determinants of solitary localization and subsequent dissemination are not fully defined. Genomic studies have identified cytogenetic abnormalities partly similar to those of multiple myeloma, including t(4;14), t(14;16), 13q deletions and chromosome 1 abnormalities, but at lower frequency and with less complexity.

A central hypothesis explaining solitary localization is "microenvironmental dependence": neoplastic plasma cells benefit from specific growth and survival signals provided by bone tissue or the extracellular matrix of soft tissues. In SBP, interactions with stromal cells, osteoblasts and osteoclasts may promote local proliferation, whereas the capacity for systemic dissemination is not demonstrable at diagnosis but may emerge over time; in EMP, common sites including the upper respiratory tract, paranasal sinuses and gastrointestinal tract provide an immune and stromal environment favorable to maintenance of the clone.

This microenvironmental dependence helps explain why many solitary plasmacytomas remain localized for years, but also why they may progress to disseminated disease after new genetic or epigenetic events or microenvironmental changes allow escape from local constraints.

From a pathophysiologic perspective, the tumor mass progressively expands at its site of origin and causes predominantly local damage:

• In SBP, osteolytic destruction results from production of osteoclast-activating cytokines, including RANKL and IL-6, by plasma cells and stromal cells, promoting bone resorption and, in advanced cases, pathologic fractures, vertebral collapse or refractory pain.
• In EMP, the mass may invade adjacent structures, including the nasal cavities, paranasal sinuses, oropharynx, larynx and gastrointestinal tract, causing compressive symptoms, airway obstruction, epistaxis, dysphagia or focal neurologic symptoms at critical sites.

Unlike multiple myeloma, anemia, renal failure and hypercalcemia attributable to systemic plasma cell proliferation are absent at diagnosis. A serum or urinary monoclonal component may be present; its persistence after local treatment has prognostic value and requires monitoring even without documented dissemination.

Progression to multiple myeloma is the crucial event in the natural history of solitary plasmacytoma. A substantial proportion of patients eventually develop evidence of systemic disease, often after years of apparent stability. Mechanisms underlying this evolution include acquisition of new genetic abnormalities allowing plasma cells to colonize the bone marrow at multiple sites and evade inhibitory signals from the local microenvironment.

Early identification of progression-risk markers mainly concerns persistence of the monoclonal component and minimal bone marrow involvement; cytogenetic abnormalities remain under investigation and are not a validated independent clinical predictor.

Clinical manifestations

The clinical manifestations of solitary plasmacytoma are closely related to the anatomic site, tumor volume and degree of local invasiveness, reflecting the circumscribed nature of the disease. Unlike multiple myeloma, systemic symptoms are typically absent in the early stages because diffuse bone marrow involvement and systemic organ impairment are exclusion criteria for this diagnosis. The presentation may be subtle and diagnosis is often delayed, particularly in extramedullary forms.

In solitary bone plasmacytoma (SBP), the cardinal symptom is localized pain, persistent and progressive and often described as deep, dull and resistant to common analgesics. Initially, it may be attributed to degenerative osteoarticular disease or minor trauma, but it tends to worsen, become nocturnal and, in advanced cases, limit function of the affected segment. Local progression may cause palpable swelling, bone deformity or visible alteration of local anatomy, depending on the skeletal site involved.

In weight-bearing skeletal segments, particularly the vertebrae, long bones and pelvis, progressive bone erosion may cause vertebral collapse, postural deformity, radicular pain, joint instability and, in the most severe cases, neurologic symptoms from spinal cord or nerve root compression, including weakness, paresthesia and paraplegia.

Careful physical examination may reveal focal tenderness, a firm swelling fixed to deep planes, functional limitation of the affected limb or segment and, with vertebral involvement, focal neurologic signs requiring urgent diagnostic evaluation.

In solitary extramedullary plasmacytoma (EMP), the clinical presentation is highly heterogeneous and depends on the involved organ or tissue. The most commonly affected sites are the upper respiratory tract, including the nasal cavities, paranasal sinuses, nasopharynx, oropharynx and larynx, where the tumor presents with insidious symptoms such as:

• Nasal obstruction, persistent rhinorrhea and recurrent epistaxis;
• Dysphonia, foreign-body sensation, progressive dysphagia and referred otalgia;
• Facial pain, headache, local deformity or, in more advanced cases, visible swelling of the face or neck.

Growth in deep soft tissues may initially be asymptomatic, making clinical recognition particularly difficult, especially in the absence of visible or palpable abnormalities. Only progressive enlargement with invasion of adjacent structures or compression of neural and vascular pathways leads to clinically significant symptoms.

At less typical sites, including the gastrointestinal tract, skin, lungs, salivary glands, orbit and central nervous system, the clinical picture reflects the affected organ and may include abdominal pain, swallowing disorders, intestinal obstruction, subcutaneous nodules, visual changes or, rarely, focal neurologic deficits.

A particularly important feature is the absence of systemic symptoms at diagnosis. Anemia, renal failure, hypercalcemia, recurrent infections and severe fatigue are usually absent, and their presence should prompt further investigation to exclude systemic disease. Detection of a serum or urinary monoclonal component (M spike), present in approximately one third of patients, causes no direct symptoms and is a supportive laboratory finding used mainly for longitudinal monitoring and assessment of progression risk.

The medical history should specifically assess for:

• Persistent nontraumatic bone pain with insidious progression and resistance to conventional analgesics;
• Obstructive upper-airway symptoms or dysfunction of organs related to the extramedullary mass;
• Signs of nerve compression, including paresthesia, motor deficits, sensory changes and paraplegia;
• Unconfirmed environmental or inflammatory associations as causal factors;
• Absence of systemic symptoms characteristic of multiple myeloma.

Clinical evaluation should be integrated with careful general and regional physical examination to identify palpable masses, skeletal deformity, neurologic deficits and signs suggestive of local compression or infiltration.

The diversity of manifestations and often paucisymptomatic nature of plasmacytoma require a high index of clinical suspicion, particularly in adults with atypical bone pain, persistent swelling or compressive symptoms not explained by other disorders.

Investigations and diagnosis

The diagnostic process for solitary plasmacytoma is one of the most complex challenges in hematologic oncology and requires rigorous integration of clinical, instrumental, laboratory and pathologic data to distinguish this entity from early multiple myeloma and from all other conditions mimicking an isolated plasma cell lesion. The pathway begins with clinical suspicion prompted by localized symptoms such as persistent bone pain, swelling or compressive symptoms in the absence of systemic signs, but clinical findings alone are never sufficient to establish the diagnosis.

The first stage of the diagnostic workup is imaging, which now uses increasingly sophisticated and integrated technologies. In osseous forms, conventional radiography may suggest a single well-defined lytic lesion without reactive sclerosis, but it often cannot fully assess tumor extent. CT and especially MRI allow precise definition of tumor volume, cortical destruction and, in vertebral lesions, involvement of paravertebral soft tissues and spinal cord or nerve root compression, which may remain clinically silent until advanced disease. Whole-body MRI is currently considered the most sensitive method for identifying occult foci of plasma cell proliferation, even in the absence of evident radiologic abnormalities.

When extramedullary plasmacytoma is suspected, imaging should be selected according to the involved site. CT and MRI of the head and neck, chest, abdomen or pelvis delineate the mass and its relationship to surrounding vascular, neural and lymphatic structures. In all cases, 18F-FDG PET/CT has a central role in global disease assessment by excluding multiple sites, detecting extramedullary lesions missed by other investigations and directing biopsy toward areas of greatest metabolic activity. Confirmation of a single hypermetabolic lesion without other suspicious areas strongly supports solitary plasmacytoma.

At the same time, laboratory evaluation is indispensable. Serum electrophoresis and testing for a monoclonal component in urine are essential not only to detect an M-protein but especially to exclude smoldering or symptomatic myeloma. Measurement of serum free light chains, integrated with immunofixation typing, can identify minor abnormalities missed by conventional methods. An isolated low-level, nonprogressive monoclonal component does not exclude solitary plasmacytoma and must always be interpreted in relation to the absence of organ damage.

A crucial diagnostic step is bone marrow biopsy. In pure plasmacytoma, clonal bone marrow plasma cells are absent; a clonal proportion below 10% defines plasmacytoma with minimal bone marrow involvement and increases progression risk. A proportion of 10% or more fulfills the bone marrow component of myeloma criteria, but active myeloma also requires a myeloma-defining event or attributable CRAB damage.

Standard laboratory testing, including complete blood count, creatinine, calcium and protein studies, is essential to identify anemia, renal failure or hypercalcemia. These abnormalities support active myeloma only when attributable to plasma cell proliferation and when the overall diagnostic criteria are fulfilled.

The diagnosis of solitary plasmacytoma is therefore based on the rigorously verified coexistence of the following criteria:

• A single osseous or extramedullary plasma cell lesion documented by imaging and confirmed histologically;
• Absence of other masses or osteolytic lesions on whole-body CT or PET/CT;
• Absence of clonal bone marrow plasma cells in pure plasmacytoma, or a clonal proportion below 10% in plasmacytoma with minimal bone marrow involvement;
• Absence of myeloma-defining events or CRAB damage attributable to systemic plasma cell proliferation;
• A possible low-level serum or urinary monoclonal component not associated with organ damage.

Diagnostic reasoning cannot, however, be reduced to a simple sum of criteria. Differential diagnosis must always be rigorous, with particular attention to conditions that mimic a solitary lesion, including metastases from solid tumors, large-cell lymphomas, primary bone or soft-tissue sarcomas and chronic granulomatous infections. These require multidisciplinary integration of clinical, radiologic and histopathologic data.

Finally, in the most complex cases, advanced molecular biology techniques and multidisciplinary discussion at specialist centers may refine the diagnosis and guide treatment and follow-up according to current international criteria.

Treatment and prognosis

Management of solitary plasmacytoma is a rapidly evolving field in which treatment must be rigorously individualized according to the site, size and local extent of the lesion, biologic prognostic factors and the patient's general condition. The main practical distinction concerns the two clinical variants, solitary bone plasmacytoma (SBP) and solitary extramedullary plasmacytoma (EMP), which share fundamental principles but differ in treatment response and natural history.

The therapeutic cornerstone for both forms is definitive-dose radiotherapy, which achieves very high rates of local control. Its use is based on the radiosensitivity of neoplastic plasma cells and the possibility of eradicating the local clone while preserving the function of adjacent organs. In SBP, the recommended dose is generally 40-50 Gy delivered in daily fractions to cover the entire tumor volume and a margin of surrounding healthy tissue to prevent marginal recurrence. Planning must be meticulous, particularly at vertebral sites, to minimize neurologic complications.

In EMP, radiotherapy is the treatment of choice in the great majority of cases and produces local remission rates above 90%. The anatomic variability of extramedullary sites requires individualized planning, often in collaboration with otolaryngologic, maxillofacial or gastrointestinal surgeons, to define target volumes precisely and evaluate potential late toxicity.

Surgery is indicated in a selected subgroup of patients, mainly for accessible extramedullary disease or when the mass creates an imminent risk of mechanical complications, including spinal cord compression, acute airway or digestive tract obstruction or uncontrolled bleeding. Radical resection may be considered only when complete removal is likely without substantial functional damage and should always be followed by adjuvant radiotherapy when margins are uncertain or positive. In osseous disease, surgery is generally limited to orthopedic complications such as pathologic fractures, vertebral instability and spinal cord decompression.

The role of systemic chemotherapy in solitary plasmacytoma remains marginal and controversial. Available evidence does not support routine chemotherapy in the absence of systemic progression because adding alkylating agents or myeloma-like regimens has not shown a significant impact on progression-free survival. However, when established clinical risk factors such as persistence of a serum monoclonal component after local treatment or documented minimal bone marrow infiltration are present, some centers propose intensive monitoring or early treatment strategies, potentially within controlled clinical trials.

Post-treatment monitoring is crucial because solitary plasmacytoma, particularly the osseous form, may progress over time to systemic multiple myeloma. Follow-up includes periodic clinical, radiologic, whole-body MRI or PET/CT, and laboratory assessment, including serum electrophoresis, immunofixation and serum free light chains, with closer intervals during the first 2-3 years and progressively less frequent assessment in patients with stable complete remission.

The prognosis of solitary plasmacytoma differs substantially between the two main forms. In patients with EMP, the risk of progression to multiple myeloma is lower than in SBP but remains approximately 25-35% at 10 years; overall survival varies with age, site and cohort characteristics and cannot be accurately summarized by a uniform value above 80-90%. In SBP, the probability of transformation to multiple myeloma remains high, approximately 65-84% at 10 years, even after apparent local control. The main predictors of progression are persistence or recurrence of the serum monoclonal component and minimal residual bone marrow infiltration; the independent prognostic role of genetic abnormalities has not yet been validated. Overall survival is strongly influenced by age, comorbidities and prompt recognition of progression to myeloma, which permits timely initiation of appropriate systemic therapy.

In recent years, therapeutic prospects have evolved rapidly with the introduction of novel immunomodulatory agents, monoclonal antibodies and proteasome inhibitors, which are currently being studied in clinical trials including high-risk forms. Early identification of patients who may be candidates for innovative treatment strategies, integrated with molecular disease characterization, represents the frontier of personalized medicine in this field.

In summary, solitary plasmacytoma should be managed at hematology referral centers by multidisciplinary teams to ensure maximal treatment individualization and optimal monitoring of progression risk through integration of clinical, pathologic, imaging and advanced molecular data.

Complications

The complications of solitary plasmacytoma reflect both the biologic nature of the disease and the long-term effects of local treatment, with a clear distinction between problems related to the site of the tumor mass and those arising from potential progression to systemic disease. Complications must be considered within the dynamic natural history of this neoplasm, which may remain locally stable for a long time but can sometimes progress abruptly to multiple myeloma.

In osseous disease, skeletal complications are the most immediate and frequent. Progressive destruction of bone by the osteolytic activity of plasma cells and the local microenvironment may cause pathologic fractures, vertebral collapse, skeletal deformity and, in spinal lesions, spinal cord or nerve root compression. These events not only impair quality of life but may cause permanent disability, chronic pain and a need for urgent surgical or orthopedic intervention. Rarely, an expanding mass at a critical site may compromise vital organ function, as with infiltration of cranial or pelvic bones.

In extramedullary plasmacytoma, complications depend closely on the affected organ and the mass effect on adjacent structures. Tumors of the upper respiratory tract may cause progressive airway obstruction, worsening dysphagia, recurrent bleeding, loss of voice or secondary infections. At deep sites, complications may develop insidiously as neurologic symptoms, intestinal obstruction or visual or neurologic impairment depending on location.

A central issue is the risk of progression to multiple myeloma, the most concerning and clinically relevant systemic complication. Transition from localized to systemic disease may be subtle and may be preceded by a persistent serum monoclonal component or minimal bone marrow infiltration not recognized initially. Progression is often marked by classic myeloma manifestations, including anemia, renal failure, hypercalcemia, recurrent infections and diffuse osteoarticular pain, which represent a turning point in the clinical course and require systemic treatment according to multiple myeloma guidelines.

Equally important are treatment-related complications. Although radiotherapy is the therapeutic cornerstone, it may cause acute adverse effects including skin erythema, mucositis and fatigue and late complications such as tissue fibrosis, osteonecrosis, second primary cancers in irradiated fields and, at particularly sensitive sites, permanent neurologic or hormonal deficits. Surgery, especially in cranio-cervical or vertebral regions, carries risks of bleeding, infection, nerve injury and functional loss and, in complex cases, may require extensive reconstruction or prolonged rehabilitation.

Possible psychological and social complications must also be considered. Uncertainty about prognosis, the risk of recurrence or systemic progression, functional impairment and the need for lifelong follow-up can profoundly affect quality of life for patients and their families.

Optimal management of complications therefore requires a proactive multidisciplinary approach integrating preventive strategies, including orthopedic protection of bones at risk and radiologic and laboratory surveillance, prompt intervention for acute and chronic complications, psychological support and individualized rehabilitation. Only close clinical surveillance and effective communication among healthcare professionals can limit the impact of the disease and its treatment while maintaining the best possible quality of life.

References
1. Soutar R et al. Guidelines on the diagnosis and management of solitary plasmacytoma of bone and solitary extramedullary plasmacytoma. British Journal of Haematology. 124, 6, 2004, 717-726.
2. Caers J et al. Diagnosis, treatment, and response assessment in solitary plasmacytoma: updated recommendations from a European Expert Panel. Journal of Hematology & Oncology. 11, 1, 2018, 10.
3. Dores GM et al. Plasmacytoma of bone, extramedullary plasmacytoma, and multiple myeloma: incidence and survival in the United States, 1992-2004. British Journal of Haematology. 144, 1, 2009, 86-94.
4. Ozsahin M et al. Outcomes and patterns of failure in solitary plasmacytoma: a multicenter Rare Cancer Network study of 258 patients. International Journal of Radiation Oncology, Biology, Physics. 64, 1, 2006, 210-217.
5. Rajkumar SV et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncology. 15, 12, 2014, e538-e548.
6. Paiva B et al. Multiparameter flow cytometry for staging of solitary bone plasmacytoma: new criteria for risk of progression to myeloma. Blood. 124, 8, 2014, 1300-1303.
7. Cavo M et al. Role of 18F-FDG PET/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the International Myeloma Working Group. Lancet Oncology. 18, 4, 2017, e206-e217.
8. Elsayad K et al. Maximizing the Clinical Benefit of Radiotherapy in Solitary Plasmacytoma: An International Multicenter Analysis. Cancers. 12, 3, 2020, 676.
9. Shen X et al. Survival trends and prognostic factors for patients with extramedullary plasmacytoma: A population-based study. Frontiers in Oncology. 12, 2022, 1052903.
10. Tsang RW et al. Radiation Therapy for Solitary Plasmacytoma and Multiple Myeloma: Guidelines From the International Lymphoma Radiation Oncology Group. International Journal of Radiation Oncology, Biology, Physics. 101, 4, 2018, 794-808.